Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

BACKGROUND: Therapeutic cancer vaccines have shown activity in metastatic castration-resistant prostate cancer (mCRPC), and methods are being assessed to enhance their efficacy. Ipilimumab is an antagonistic monoclonal antibody that binds cytotoxic T-lymphocyte-associated protein 4, an immunomodulat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet Oncol
Hlavní autoři: Madan, Ravi A, Mohebtash, Mahsa, Arlen, Philip M, Vergati, Matteo, Rauckhorst, Myrna, Steinberg, Seth M, YTsang, Kwong, Poole, Diane J, Parnes, Howard L, Wright, John J, Dahut, William L, Schlom, Jeffrey, Gulley, James L
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6359905/
https://ncbi.nlm.nih.gov/pubmed/22326924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(12)70006-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky